Related Experiment Video
Updated: Oct 8, 2025

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
Published on: July 21, 2023
Fibrinolytic Enzyme - An Overview.
Parveen Abdul Rahim1, Devika Rengaswamy1
1Department of Biotechnology, Aarupadai Institute of Technology, Vinayaka Missions University, Chennai, India.
This review explores fibrinolytic enzymes, natural compounds that break down fibrin, as potential treatments for cardiovascular diseases (CVDs). It examines their mechanisms, diverse origins, and therapeutic promise as alternatives to conventional CVD therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiology
Background:
- Cardiovascular diseases (CVDs) are leading global causes of mortality, encompassing conditions like heart attack, stroke, and hypertension.
- Current CVD treatments such as surgery and medications have limitations and adverse effects.
- Fibrinolytic agents, which degrade fibrin, offer a potential therapeutic avenue for CVDs.
Purpose of the Study:
- To review fibrinolytic enzymes, their mechanisms of action, and their diverse natural sources.
- To evaluate the therapeutic potential of these enzymes in treating cardiovascular diseases.
- To highlight fibrinolytic enzymes as promising alternatives to conventional CVD treatments.
Main Methods:
- Literature review of scientific databases focusing on fibrinolytic enzymes and cardiovascular diseases.
- Analysis of biochemical mechanisms by which fibrinolytic enzymes degrade fibrin.
- Compilation of information on the various biological sources of fibrinolytic enzymes.
Main Results:
- Fibrinolytic enzymes, including streptokinase, nattokinase, and urokinase, are derived from bacteria, fungi, plants, and other organisms.
- These enzymes exhibit diverse mechanisms for fibrin degradation.
- Various fibrinolytic enzymes show significant therapeutic potential for cardiovascular conditions.
Conclusions:
- Fibrinolytic enzymes represent a promising class of therapeutic agents for cardiovascular diseases.
- Their natural origins and enzymatic mechanisms offer potential advantages over existing treatments.
- Further research into fibrinolytic enzymes could lead to novel strategies for managing CVDs.
Related Concept Videos
Clot Retraction and Fibrinolysis
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

